In this line, there is evidence that reducing uPA‐uPAR interactions results in beneficial effects on kidney lesions.36, 37 As also shown here, UPARANT does not affect (s)uPAR up‐regulation in agreement with previous findings demonstrating that blockers of the renin angiotensin system commonly used to prevent or delay DN do not affect plasma (s)uPAR in diabetic patients.38 The additional finding that the drug does not influence uPAR in podocytes is in line with the possibility that UPARANT acts downstream uPAR by presumably blocking its binding to FPRs. Here, PLAUR is linked to liver dysplastic nodule.